http://www.bloomberg.com/news/2013-...id-to-seek-banks-for-ipo-as-sale-falters.html
Some good info in this article. Bids came in under 9 billion.
"Since the buyout, Bausch & Lomb’s earnings before interest, taxes, depreciation and amortization have risen to just under $700 million from about $400 million, people familiar with the company’s financial situation have said. The company projected 2012 Ebitda of more than $700 million and double-digit revenue growth, another person said."
From another article in jan.
But, A $10 Billion Price Tag Is Not So Cheap
"B&L had around $2.5 billion in revenues with about earnings before interest, taxes, depreciation, and amortization (EBITDA) of $400 million in 2007. [1] With an estimated 6% improvement in EBITDA margins since then [7] and an expected $800 million of EBITDA in 2013 [1], estimated revenues for 2013 would be close to $3.5 billion. Thus, a $10 billion price tag would be more than 2.5 times of its expected 2013 revenues, or about 12 times of its 2013 EBITDA. The big question is if these healthcare companies would be ready to shell out that much premium for a company whose overall growth may be in tandem, with the expected market growth of mid-single digit"
Projecting double digit growth?
75% growth of EBITDA over 5 years? During the recession? Maybe. Maybe Europe and asia had that type of growth.
Why fire CEOs mid stream if they were doing that?
I don't know. Those numbers feel high.
I'm guessing their 2012 and 2013 EBITDA projections are lofty but I'm skeptical of anonymous sources and their numbers. Who knows if they're even real or just putting info out there.
There are also accounting tricks they can pull off to dress up the numbers. You'd need a forensic financial analyst to get to the bottom of those numbers.
Makes no difference now.
B&L will IPO.
JPmorgan chase work with warburg. They'll make it happen.
Get ready. Being public is a whole different beast.
Gotta hit the numbers. Every quarter or heads will roll.
Some good info in this article. Bids came in under 9 billion.
"Since the buyout, Bausch & Lomb’s earnings before interest, taxes, depreciation and amortization have risen to just under $700 million from about $400 million, people familiar with the company’s financial situation have said. The company projected 2012 Ebitda of more than $700 million and double-digit revenue growth, another person said."
From another article in jan.
But, A $10 Billion Price Tag Is Not So Cheap
"B&L had around $2.5 billion in revenues with about earnings before interest, taxes, depreciation, and amortization (EBITDA) of $400 million in 2007. [1] With an estimated 6% improvement in EBITDA margins since then [7] and an expected $800 million of EBITDA in 2013 [1], estimated revenues for 2013 would be close to $3.5 billion. Thus, a $10 billion price tag would be more than 2.5 times of its expected 2013 revenues, or about 12 times of its 2013 EBITDA. The big question is if these healthcare companies would be ready to shell out that much premium for a company whose overall growth may be in tandem, with the expected market growth of mid-single digit"
Projecting double digit growth?
75% growth of EBITDA over 5 years? During the recession? Maybe. Maybe Europe and asia had that type of growth.
Why fire CEOs mid stream if they were doing that?
I don't know. Those numbers feel high.
I'm guessing their 2012 and 2013 EBITDA projections are lofty but I'm skeptical of anonymous sources and their numbers. Who knows if they're even real or just putting info out there.
There are also accounting tricks they can pull off to dress up the numbers. You'd need a forensic financial analyst to get to the bottom of those numbers.
Makes no difference now.
B&L will IPO.
JPmorgan chase work with warburg. They'll make it happen.
Get ready. Being public is a whole different beast.
Gotta hit the numbers. Every quarter or heads will roll.